

Table 3: Repeated measures ANOVAS for secondary outcome criteria

| Clinical scales | Effects | <i>F</i> | <i>df</i> | <i>p</i> |
|---------------------|--------------------|----------|-------------|------------|
| ACQ mean | Time ¹ | 88.59 | 2.51,178.06 | < .001 *** |
| | Group ² | 0.09 | 1,71 | .76 |
| | Time * Group | 3.22 | 2.51,178.06 | .03 * |
| BSQ mean | Time ¹ | 58.33 | 2.03,143.78 | < .001 *** |
| | Group ² | 0.51 | 1,71 | .48 |
| | Time * Group | 0.82 | 2.03,143.78 | .44 |
| MI alone mean | Time ¹ | 119.96 | 1.70,120.42 | < .001 *** |
| | Group ² | 0.19 | 1,71 | .67 |
| | Time * Group | 1.05 | 1.70,120.42 | .34 |
| MI accompanied mean | Time ¹ | 68.06 | 2.05,145.37 | < .001 *** |
| | Group ² | 1.04 | 1,71 | .31 |
| | Time * Group | 0.75 | 2.05,145.37 | .48 |
| ASI sum score | Time ¹ | 112.43 | 2.04,144.94 | < .001 *** |
| | Group ² | 0.10 | 1,71 | .75 |
| | Time * Group | 1.36 | 2.04,144.94 | .26 |
| BAI sum score | Time ¹ | 50.63 | 2.48,176.25 | < .001 *** |
| | Group ² | 0.001 | 1,71 | .98 |
| | Time * Group | 0.39 | 2.48,176.25 | .72 |
| BDI II sum score | Time ¹ | 56.10 | 2.23,158.54 | < .001 *** |
| | Group ² | 0.28 | 1,71 | .60 |
| | Time * Group | 0.17 | 2.23,158.54 | .86 |
| BSI sum score | Time ¹ | 66.36 | 2.08,147.83 | < .001 *** |
| | Group ² | 0.28 | 1,71 | .60 |
| | Time * Group | 0.48 | 2.08,147.83 | .63 |
| CGI | Time ¹ | 257.93 | 2.38,169.06 | < .001 *** |
| | Group ² | 9.90 | 1,71 | .002 ** |
| | Time * Group | 1.38 | 2.38,169.06 | .26 |

¹ Factor time: t1, t4 (+~ 2 months), t10 (+~ 3 months) and t11 (+~ 4 months)

² Factor group: DCS (N = 36) vs. PBO (N = 37)

Abbreviations: DCS = D-Cycloserine, PBO = Placebo, PAS = Panic and Agoraphobia Scale, ACQ = Agoraphobic Cognitions Questionnaire, BSQ = Body Sensations Questionnaire, MI = Mobility Inventory, ASI = Anxiety Sensitivity Index, BAI = Beck Anxiety Inventory, BDI II = Beck Depression Inventory II, BSI = Brief Symptom Inventory, CGI = Clinical Global Impression.

* = $p < .05$, ** = $p < .01$, *** = $p < .001$.